Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TLR4 | O00206 | 5/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5697291 | 0.78 | ALDH1A1 (0.49) | ALDH1A1MAPTL3MBTL1GAACA1 | |
| SCHEMBL12657487 | 0.78 | ALDH1A1 (0.41) | ALDH1A1MAPTL3MBTL1GAATLR4 | |
| SCHEMBL1219343 | 0.74 | MAPT (0.59) | ALDH1A1MAPTGAAKMT2APOLB | |
| SCHEMBL1397437 | 0.74 | NPC1 (0.45) | ALDH1A1GAATLR4CA1CA2 | |
| Water SCHEMBL9787126 | 0.72 | CYP2D6 (0.47) | ALDH1A1MAPTL3MBTL1GAAKMT2A | |
| SCHEMBL16495228 | 0.72 | ALDH1A1 (0.33) | ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL1188324 | 0.72 | NPC1 (0.46) | ALDH1A1GAACA1CA2CA4 | |
| SCHEMBL12861148 | 0.71 | ALDH1A1 (0.36) | ALDH1A1MAPTL3MBTL1GAA | |
| SCHEMBL1981599 | 0.71 | CA1 (0.46) | ALDH1A1GAACA1CA2CA4 | |
| SCHEMBL28365490 | 0.71 | CA1 (0.46) | ALDH1A1GAACA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070918-A1 | Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives | SERENEX, INC. | 2008-03-20 | — | — | US | claimed |
| WO-2008024961-A1 | DIHYDROPYRIDAZINE, TETRAHYDROPYRIDINE, CHROMANONE, AND DIHYDRONAPHTHALENONE DERIVATIVES AS HEAT-SHOCK PROTEIN 90 INHIBITORS | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-20140315889-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-10-23 | — | — | US | disclosed |
| US-20140315889-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-10-23 | — | — | US | disclosed |
| US-20140315889-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-10-23 | — | — | US | disclosed |
| EP-2771321-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | Chong Kun Dang Pharmaceutical Corp. (KR) | 2014-09-03 | — | — | EP | disclosed |
| EP-2451780-B1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF 4-(ACETYLAMINO))-3-[(4-CHLORO-PHENYL)THIO]-2-METHYL-1H-INDOLE-1-ACETIC ACID | ASTRAZENECA AB (SE) | 2013-06-19 | — | — | EP | disclosed |
| EP-2451780-B1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF 4-(ACETYLAMINO))-3-[(4-CHLORO-PHENYL)THIO]-2-METHYL-1H-INDOLE-1-ACETIC ACID | ASTRAZENECA AB (SE) | 2013-06-19 | — | — | EP | disclosed |
| WO-2013062344-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013062344-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-05-02 | — | — | WO | disclosed |
| US-8227622-B2 | Pharmaceutical process and intermediates 714 | ASTRAZENECA AB (SE) | 2012-07-24 | — | — | US | disclosed |
| EP-2451780-A1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF 4- (ACETYLAMINO) ) -3- [ (4-CHLORO-PHENYL) THIO]-2-METHYL-1H-INDOLE-1-ACETIC ACID | AstraZeneca AB (SE) | 2012-05-16 | — | — | EP | disclosed |
| US-20110312945-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110046394-A1 | Pharmaceutical Process and Intermediates 714 | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046394-A1 | Pharmaceutical Process and Intermediates 714 | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046394-A1 | Pharmaceutical Process and Intermediates 714 | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| WO-2011004182-A1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF 4- (ACETYLAMINO) ) -3- [ (4-CHLORO-PHENYL) THIO] -2-METHYL-1H-INDOLE-1-ACETIC ACID | ASTRAZENECA AB (SE) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011004182-A1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF 4- (ACETYLAMINO) ) -3- [ (4-CHLORO-PHENYL) THIO] -2-METHYL-1H-INDOLE-1-ACETIC ACID | ASTRAZENECA AB (SE) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010039982-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315889-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | HDAC1, HDAC5, HDAC3 | ALDH1A1 772/4885MAPT 1106/4885L3MBTL1 4194/4885 |
| US-20110046394-A1 | Pharmaceutical Process and Intermediates 714 | CYP3A4, CYP4A11, CYP4B1 | ALDH1A1 539/4885MAPT 3154/4885L3MBTL1 4687/4885 |
| US-20080070918-A1 | Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives | QDPR, CCND2, CCND1 | ALDH1A1 143/4885MAPT 3752/4885L3MBTL1 4480/4885 |
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | ALDH1A1 199/4885MAPT 3226/4885L3MBTL1 631/4885 |
| US-20110312945-A1 | CRTH2 MODULATORS | HRH2, HRH1, NR1H2 | ALDH1A1 851/4885MAPT 4649/4885L3MBTL1 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.